New CRISPR Cas9 Technology for Enhanced RNP-Based Genome Editing
24 July 2017

One of the primary concerns with CRISPR’s use for therapeutic applications is the potential for off-target cleavage. This application note presents a new development in Cas9 technology from the life science business of Merck KGaA, Darmstadt, Germany, for addressing the problem of CRISPR off-target effects, the enhanced specificity Cas9 (eSpCas9) for ribonucleoprotein-based genome editing. In addition, discover detailed protocols for use of Cas9 RNP which has broad applications in both animal and plant models. *The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.